Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics, Inc. reported that Chief Scientific Officer Gwenn Hansen received new equity awards on February 10, 2026. She was granted an option to buy 93,750 shares of common stock at $16.45 per share, vesting monthly over three years through February 9, 2029, subject to continued service.
Hansen was also granted 42,875 restricted stock units, each representing one share of common stock. These RSUs vest in 12 equal quarterly installments over three years, beginning July 30, 2026, with shares delivered after each vesting date as long as she remains in service.
Nurix Therapeutics President and CEO Arthur T. Sands received an employee stock option grant covering 562,500 shares of common stock at an exercise price of $16.45 per share on February 10, 2026.
The option vests in 36 equal monthly installments beginning March 10, 2026, and becomes fully vested on February 9, 2029, subject to his continued service. It is scheduled to expire on February 9, 2036.
Nurix Therapeutics’ Chief Legal Officer, Christine Ring, reported a planned sale of company stock. On 02/09/2026 she sold 14,261 shares of Nurix common stock at a weighted average price of $16.6621 per share under a pre‑arranged Rule 10b5‑1 trading plan. Following this sale, she beneficially owns 42,749 shares of Nurix common stock directly.
A shareholder of NRIX has filed a Rule 144 notice to sell 14,261 common shares, with an aggregate market value of $240,297.85, through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 02/09/2026.
The shares were acquired as restricted stock units from the issuer on 05/02/2022. The filing also notes prior sales under a Rule 10b5-1 plan, including 3,760 shares sold on 01/20/2026 for $69,273.11 and 37,600 shares sold on 11/24/2025 for $641,697.02. Shares outstanding were 102,843,012 at the time referenced.
Nurix Therapeutics, Inc. Chief Scientific Officer Gwenn Hansen reported an option exercise and corresponding stock acquisition. On 02/03/2026, Hansen exercised an employee stock option for 31,333 shares of common stock at $0.84 per share, converting the derivative position to common stock. Following this transaction, Hansen directly beneficially owns 115,005 shares of Nurix common stock, and the reported option grant is fully vested with 0 derivative securities remaining.
Nurix Therapeutics, Inc.’s Chief Financial Officer, Hans van Houte, reported routine equity compensation activity and related tax sales. On January 30, 2026, several blocks of restricted stock units (RSUs) converted into common stock at $0 exercise price, including 2,887, 2,000, 3,750 and 2,859 RSUs.
To cover tax withholding from these RSU vestings, the CFO sold 3,588 shares at a weighted average price of $16.5826 and 73 shares at a weighted average price of $17.3717. The filing states these are mandatory “sell to cover” transactions, not discretionary trades. After the transactions, he directly owned 45,427 common shares and 25,725 RSUs.
Nurix Therapeutics Chief Legal Officer Christine Ring reported RSU vesting and related share sales. On January 30, 2026, multiple blocks of restricted stock units were converted into common stock at an exercise price of $0, increasing her directly held common shares.
On the same date, she sold 4,333 and 88 common shares at weighted average prices of $16.5826 and $17.3717, respectively. A footnote explains these sales were mandated "sell to cover" transactions to satisfy tax withholding on RSU vesting, not discretionary trades. After these transactions, she directly owned 57,010 common shares and held 25,725 RSUs.
Nurix Therapeutics Chief Scientific Officer Gwenn Hansen reported RSU vesting and related tax-share sales. On January 30, 2026, RSUs covering 3,207, 2,000, 3,750, and 2,859 shares were converted into common stock at $0 per share.
To cover tax withholding from these RSU vestings, Hansen sold 4,797 and 98 common shares in mandated “sell to cover” transactions at weighted average prices of $16.5826 and $17.3717. After these trades, Hansen directly beneficially owned 83,672 common shares and held 25,725 RSUs.
Nurix Therapeutics details in its annual report a broad clinical and partnering strategy built around targeted protein degradation for cancer and inflammatory diseases. The company’s wholly owned pipeline includes three clinical candidates: BTK degraders bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127), and CBL‑B inhibitor NX‑1607.
Bexobrutideg is in a potentially pivotal Phase 2 study for heavily pretreated CLL/SLL and has U.S. Fast Track and EU PRIME designations, with additional data in Waldenström macroglobulinemia. NX‑1607 shows early immune‑oncology activity across solid tumors. Nurix also highlights its DEL‑AI discovery platform, DAC technology and collaborations with Gilead, Sanofi and Pfizer, which have provided $482 million in non‑dilutive funding and could yield up to $6.1 billion in future milestones.
Nurix Therapeutics, Inc. filed a current report to note that on January 28, 2026 it issued a press release announcing its financial results for the fiscal quarter and year ended November 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference.
The company clarifies that the information provided under Item 2.02, including Exhibit 99.1, is furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings.